AbbVie | ABBV - Gross Profit On Sales

Stock Price
214.41
Daily Change
5.00 2.39%
Monthly
5.25%
Yearly
15.99%
Q2 Forecast
206.16

AbbVie reported $12.54B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Abbott USD 5.86B 675M Mar/2026
ALKERMES USD 331.33M 7M Mar/2026
Amgen USD 6.89B 415M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eisai JPY 153.41B 15.44B Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Infinity Pharmaceuticals USD 231K 59K Jun/2023
J&J USD 17.24B 642M Mar/2026
Medtronic USD 5.41B 27M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.07B 184M Mar/2026
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Zoetis USD 1.62B 20M Mar/2026